MATRIX PHARMACEUTICAL ANNOUNCES FIRST PRODUCT APPROVAL; AccuSite Injectable Gel Approved for Sale in the United Kingdom.FREMONT, Calif.--(BUSINESS WIRE)--June 4, 1996--Matrix Pharmaceutical, Inc. (NNM/MATX) today announced that the Medicines Control Agency (MCA MCA in full Music Corporation of America Entertainment conglomerate. It was founded in Chicago in 1924 by Jules Stein as a talent agency. In the 1960s it bought Decca Records and Universal Pictures, and today it produces films, music, and television shows. ) in the United Kingdom has granted a product license to Matrix Pharmaceutical, Ltd., its wholly-owned subsidiary, for AccuSite (fluorouracil/epinephrine) Injectable Gel as a treatment for external genital warts genital warts: see human papillomavirus. . Genital warts, known in medical terms as condylomata acuminata, are a sexually transmitted disease sexually transmitted disease (STD) or venereal disease, term for infections acquired mainly through sexual contact. Five diseases were traditionally known as venereal diseases: gonorrhea, syphilis, and the less common granuloma inguinale, caused by infection with the human papillomavirus (HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) ). The incidence of genital warts is increasing worldwide. In Europe, it is estimated that approximately 1.5 million new patients are diagnosed with genital warts each year. "In the U.K., approximately 25% of all patient visits to Genito/Urinary (GU) clinics are genital warts related," stated David M. Hill, M.D., vice president and medical director of Matrix Pharmaceutical, Ltd. "Recognizing the need for treatment alternatives for this difficult-to-treat disease, we look forward to introducing AccuSite& as a new treatment option for these patients. In a clinical trial of AccuSite, 77% of genital wart lesions were completely resolved following treatment," he added. "This first approval for a Matrix-developed product represents the achievement of a significant milestone for the company," noted Craig R. McMullen, president and chief executive officer of Matrix Pharmaceutical, Inc. "With approval in hand, we continue to prepare for the European launch of the product. Matrix Ltd. has also filed Market Authorization Applications (MAAs) in France, Sweden, Italy and Germany, and may submit a Mutual Recognition filing to other members of the European community in the near future." In the United States, the company's New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for AccuSite to the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) is currently under review. AccuSite is also under investigation as a treatment for nonmelanoma skin cancers. International clinical trials are currently underway for basal cell cancer Basal cell cancer The most common form of skin cancer; it usually appears as one or several nodules having a central depression. It rarely spreads (metastisizes), but is locally invasive. Mentioned in: Cryotherapy in the U.K., Australia and the United States. The results of a Phase II study in patients with squamous cell carcinoma squamous cell carcinoma n. A carcinoma that arises from squamous epithelium and is the most common form of skin cancer. Also called cancroid, epidermoid carcinoma. were recently presented at the Clinical Dermatology 2000 meeting in Vancouver, B.C. Located in Fremont, California, Matrix Pharmaceutical, Inc. uses its proprietary drug delivery technologies to develop novel site-specific treatments for cancer and serious skin diseases. CONTACT: Maxtrix Pharmaceutical Inc. U.S.A. James R. Glynn, 510/742-9900 or Matrix Pharmaceutical, Ltd., U.K. David M. Hill, M.D., 011-441-420-544-510 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion